Kenneth Gordon to Middle Aged
This is a "connection" page, showing publications Kenneth Gordon has written about Middle Aged.
Connection Strength
1.226
-
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study. J Am Acad Dermatol. 2025 Jun; 92(6):1235-1242.
Score: 0.057
-
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023 04; 5(4):e200-e207.
Score: 0.050
-
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 07 01; 158(7):735-744.
Score: 0.047
-
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 02 06; 397(10273):475-486.
Score: 0.043
-
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. Am J Clin Dermatol. 2020 Dec; 21(6):881-890.
Score: 0.042
-
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. JAMA Dermatol. 2020 12 01; 156(12):1344-1353.
Score: 0.042
-
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Adv Ther. 2020 01; 37(1):364-380.
Score: 0.039
-
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2020 Dec; 31(8):763-768.
Score: 0.039
-
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.
Score: 0.036
-
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov; 32(11):1940-1949.
Score: 0.036
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-431.
Score: 0.032
-
Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 02; 28(1):3-7.
Score: 0.031
-
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. J Eur Acad Dermatol Venereol. 2015 Apr; 29(4):767-76.
Score: 0.028
-
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014 Dec; 71(6):1176-82.
Score: 0.028
-
Understanding therapeutic pathways and comorbidities in psoriasis. Semin Cutan Med Surg. 2014 Mar; 33(2 Suppl 2):S20-3.
Score: 0.027
-
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012 Feb; 132(2):304-14.
Score: 0.023
-
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012 May; 66(5):742-51.
Score: 0.022
-
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012 Feb; 66(2):241-51.
Score: 0.022
-
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat. 2007; 18(1):13-8.
Score: 0.016
-
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006 Oct; 55(4):598-606.
Score: 0.016
-
Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S101-11.
Score: 0.015
-
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat. 2006; 17(1):9-17.
Score: 0.015
-
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther. 2005 Sep; 27(9):1317-28.
Score: 0.015
-
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies. Am J Clin Dermatol. 2025 Nov; 26(6):967-979.
Score: 0.015
-
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares. J Clin Invest. 2025 Sep 02; 135(17).
Score: 0.015
-
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. J Am Acad Dermatol. 2025 Sep; 93(3):644-653.
Score: 0.014
-
The efficacy of alefacept in the treatment of chronic plaque psoriasis. J Cutan Med Surg. 2004 Dec; 8 Suppl 2:3-9.
Score: 0.014
-
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52?weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024 Aug; 38(8):1543-1554.
Score: 0.013
-
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2024 02 01; 160(2):204-209.
Score: 0.013
-
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17; 290(23):3073-80.
Score: 0.013
-
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 2003 Dec; 139(12):1563-70.
Score: 0.013
-
Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003 Dec; 2(6):624-8.
Score: 0.013
-
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol. 2003 Nov; 49(5):816-25.
Score: 0.013
-
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023 10 28; 402(10412):1541-1551.
Score: 0.013
-
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 02 06; 397(10273):487-498.
Score: 0.011
-
Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology. 2021; 237(1):46-55.
Score: 0.010
-
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr; 82(4):936-945.
Score: 0.010
-
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2020 Feb; 34(2):301-309.
Score: 0.010
-
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.
Score: 0.010
-
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019 Dec; 46(12):1141-1152.
Score: 0.010
-
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018 10 04; 379(14):1313-1321.
Score: 0.009
-
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018 Aug; 32(8):1297-1304.
Score: 0.009
-
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 2018 06 01; 154(6):676-683.
Score: 0.009
-
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 08; 179(2):320-328.
Score: 0.009
-
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018 Aug; 79(2):294-301.e6.
Score: 0.009
-
The Evolving Landscape of Psoriasis Treatment. Semin Cutan Med Surg. 2018 Feb; 37(2S):S39-S43.
Score: 0.009
-
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health. 2017 09; 20(8):1174-1179.
Score: 0.008
-
Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. J Am Acad Dermatol. 2017 Jun; 76(6):1045-1053.e3.
Score: 0.008
-
Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol. 1997 Mar; 136(3):415-20.
Score: 0.008
-
Bowen's disease of the distal digit. Outcome of treatment with carbon dioxide laser vaporization. Dermatol Surg. 1996 Aug; 22(8):723-8.
Score: 0.008
-
Serious infections in hospitalized patients with psoriasis in the United States. J Am Acad Dermatol. 2016 Aug; 75(2):287-96.
Score: 0.008
-
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28; 375(4):345-56.
Score: 0.008
-
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 06 01; 152(6):661-9.
Score: 0.008
-
The inpatient burden of psoriasis in the United States. J Am Acad Dermatol. 2016 Jul; 75(1):33-41.
Score: 0.008
-
Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016 Jul; 75(1):77-82.e7.
Score: 0.008
-
Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. J Am Acad Dermatol. 1996 Feb; 34(2 Pt 1):304-6.
Score: 0.008
-
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015 Oct; 373(14):1318-28.
Score: 0.007
-
The experience of pain and redness in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2015 Oct; 26(5):401-5.
Score: 0.007
-
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015 Jul 09; 373(2):136-44.
Score: 0.007
-
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul; 73(1):37-49.
Score: 0.007
-
Carbon dioxide laser vaporization for Bowen's disease of the finger. Arch Dermatol. 1994 Oct; 130(10):1250-2.
Score: 0.007
-
Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat. 2013 Aug; 24(4):255-60.
Score: 0.006
-
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec; 27(12):1535-45.
Score: 0.006
-
Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013 Oct; 24(5):356-60.
Score: 0.006
-
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct; 27(10):1252-61.
Score: 0.006
-
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012 Apr; 166(4):861-72.
Score: 0.006
-
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012 Mar; 11(3):300-12.
Score: 0.006
-
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012 Aug; 67(2):245-56.
Score: 0.006
-
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24; 306(8):864-71.
Score: 0.006
-
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol. 2011 Feb; 64(2):263-74.
Score: 0.005
-
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010 Sep; 63(3):448-56.
Score: 0.005
-
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65.
Score: 0.005
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17; 371(9625):1665-74.
Score: 0.004
-
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008 Feb; 144(2):200-7.
Score: 0.004
-
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan; 58(1):106-15.
Score: 0.004
-
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007 Jun; 143(6):719-26.
Score: 0.004
-
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007; 18(6):341-50.
Score: 0.004
-
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007 Apr; 56(4):598-603.
Score: 0.004
-
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol. 2006 May; 45(5):605-14.
Score: 0.004
-
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2006 Apr; 54(4 Suppl 1):S164-70.
Score: 0.004
-
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006 Jan 07; 367(9504):29-35.
Score: 0.004
-
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. J Cutan Med Surg. 2005 Dec; 9(6):303-12.
Score: 0.004
-
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005 Jun; 141(6):683-7.
Score: 0.004
-
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005 May; 152(5):954-60.
Score: 0.004
-
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33.
Score: 0.004
-
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005 Jan; 141(1):31-8.
Score: 0.004
-
A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003 Dec; 139(12):1627-32; discussion 1632.
Score: 0.003
-
Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery. Dermatol Surg. 2002 Dec; 28(12):1107-14; discussion 1114.
Score: 0.003
-
Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease. Dermatol Surg. 2000 Apr; 26(4):371-4.
Score: 0.003
-
The clinical spectrum of ocular lymphoma. Cancer. 1993 Aug 01; 72(3):843-9.
Score: 0.002